title: NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
authors.forename: L
authors.initials: L
authors.lastname: Doepel
authors.forename: G
authors.initials: G
authors.lastname: Folkers
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects*; D018925:Chemokines / Q000276:immunology*; D002986:Clinical Trials as Topic; D002999:Clone Cells; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology*; D016049:Didanosine / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D016753:Interleukin-10 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D019829:Nevirapine; D011725:Pyridines / Q000627:therapeutic use; D018121:Receptors, Cytokine / Q000276:immunology; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects*; D016047:Zalcitabine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018925:Chemokines; D017320:HIV Protease Inhibitors; D011725:Pyridines; D018121:Receptors, Cytokine; D018894:Reverse Transcriptase Inhibitors; D016753:Interleukin-10; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D019829:Nevirapine; D016049:Didanosine; D019438:Ritonavir